Please use this identifier to cite or link to this item:
http://hdl.handle.net/11452/29524
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.date.accessioned | 2022-11-21T12:45:10Z | - |
dc.date.available | 2022-11-21T12:45:10Z | - |
dc.date.issued | 2013-05 | - |
dc.identifier.citation | Cansev, M. vd. (2013). "Neuroprotective effects of uridine in a rat model of neonatal hypoxic-ischemic encephalopathy". Neuroscience Letters, 542, 65-70. | en_US |
dc.identifier.issn | 0304-3940 | - |
dc.identifier.issn | 1872-7972 | - |
dc.identifier.uri | https://doi.org/10.1016/j.neulet.2013.02.035 | - |
dc.identifier.uri | https://www.sciencedirect.com/science/article/pii/S0304394013001699 | - |
dc.identifier.uri | http://hdl.handle.net/11452/29524 | - |
dc.description.abstract | Neonatal hypoxic ischemic encephalopathy (HIE) is a major cause of neurological disability requiring newer therapeutic strategies. Uridine is the principal circulating pyrimidine in humans and a substrate for nucleotides and membrane phospholipids. The objective of this study was to investigate the effects of uridine in a neonatal rat model of HIE. Rat pups subjected to hypoxic ischemic insult on postnatal day 7 were injected intraperitoneally with either saline or uridine (100, 300 or 500 mg/kg) for three consecutive days and brains were collected for evaluation of brain infarct volume and apoptosis. Compared with Control group, uridine at 300 and 500 mg/kg doses significantly reduced percent infarct volume, TUNEL(+) cell ratio and active Caspase-3 immunoreactivity in the cortex, as well as in CA1 and CA3 regions of the hippocampus. Uridine (300 and 500 mg/kg) also decreased active Caspase-3 expression in the ipsilateral hemisphere. These data indicate that uridine dose-dependently reduces brain injury in a rat model of neonatal HIE by decreasing apoptosis. | en_US |
dc.language.iso | en | en_US |
dc.publisher | Elsevier Ireland | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | Neurosciences & neurology | en_US |
dc.subject | Uridine | en_US |
dc.subject | Neonatal | en_US |
dc.subject | Hypoxic-ischemic encephalopathy | en_US |
dc.subject | Neuroprotection | en_US |
dc.subject | Apoptosis | en_US |
dc.subject | Rat | en_US |
dc.subject | Deprivation-induced death | en_US |
dc.subject | Cdp-choline levels | en_US |
dc.subject | Docosahexaenoic acid | en_US |
dc.subject | Brain-damage | en_US |
dc.subject | Cytidine | en_US |
dc.subject | Nucleotides | en_US |
dc.subject | Hypothermia | en_US |
dc.subject | Prevents | en_US |
dc.subject | Plasma | en_US |
dc.subject | Growth | en_US |
dc.subject.mesh | Animals | en_US |
dc.subject.mesh | Animals, newborn | en_US |
dc.subject.mesh | Apoptosis | en_US |
dc.subject.mesh | Brain | en_US |
dc.subject.mesh | Brain infarction | en_US |
dc.subject.mesh | Caspase 3 | en_US |
dc.subject.mesh | Cerebral cortex | en_US |
dc.subject.mesh | Hypoxia-ischemia, brain | en_US |
dc.subject.mesh | Neuroprotective agents | en_US |
dc.subject.mesh | Rats | en_US |
dc.subject.mesh | Rats, sprague-dawley | en_US |
dc.subject.mesh | Uridine | en_US |
dc.title | Neuroprotective effects of uridine in a rat model of neonatal hypoxic-ischemic encephalopathy | en_US |
dc.type | Article | en_US |
dc.identifier.wos | 000318831100013 | tr_TR |
dc.identifier.scopus | 2-s2.0-84876725421 | tr_TR |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | tr_TR |
dc.contributor.department | Uludağ Üniversitesi/Fen-Edebiyat Fakültesi/Biyoloji Bölümü. | tr_TR |
dc.contributor.department | Uludağ Üniversitesi/Tıp Fakültesi/Histoloji ve Embriyoloji Anabilim Dalı. | tr_TR |
dc.contributor.department | Uludağ Üniversitesi/Tıp Fakültesi/Fizyoloji Bölümü. | tr_TR |
dc.contributor.department | Uludağ Üniversitesi/Tıp Fakültesi/Farmakoloji Anabilim Dalı. | tr_TR |
dc.contributor.department | Uludağ Üniversitesi/Tıp Fakültesi/Neonatoloji Anabilim Dalı. | tr_TR |
dc.relation.bap | T/U 2009-2 | tr_TR |
dc.contributor.orcid | 0000-0001-6466-5042 | tr_TR |
dc.contributor.orcid | 0000-0002-5206-1185 | tr_TR |
dc.contributor.orcid | 0000-0002-5206-1185 | tr_TR |
dc.contributor.orcid | 0000-0001-5757-8450 | tr_TR |
dc.identifier.startpage | 65 | tr_TR |
dc.identifier.endpage | 70 | tr_TR |
dc.identifier.volume | 542 | tr_TR |
dc.relation.journal | Neuroscience Letters | en_US |
dc.contributor.buuauthor | Cansev, Mehmet | - |
dc.contributor.buuauthor | Minbay, Zehra | - |
dc.contributor.buuauthor | Gören, Bülent | - |
dc.contributor.buuauthor | Yaylagül, Esra Örenlili | - |
dc.contributor.buuauthor | Çetinkaya, Merih | - |
dc.contributor.buuauthor | Köksal, Nilgün | - |
dc.contributor.buuauthor | Alkan, Tülin | - |
dc.contributor.researcherid | AAH-1792-2021 | tr_TR |
dc.contributor.researcherid | AAH-1718-2021 | tr_TR |
dc.contributor.researcherid | ABC-1475-2020 | tr_TR |
dc.contributor.researcherid | AAG-8393-2021 | tr_TR |
dc.contributor.researcherid | V-4209-2018 | tr_TR |
dc.contributor.researcherid | M-9071-2019 | tr_TR |
dc.contributor.researcherid | ABH-4915-2020 | tr_TR |
dc.identifier.pubmed | 23458674 | tr_TR |
dc.subject.wos | Neurosciences | en_US |
dc.indexed.wos | SCIE | en_US |
dc.indexed.scopus | Scopus | en_US |
dc.indexed.pubmed | PubMed | en_US |
dc.wos.quartile | Q3 | en_US |
dc.contributor.scopusid | 8872816100 | tr_TR |
dc.contributor.scopusid | 8220935200 | tr_TR |
dc.contributor.scopusid | 6602543716 | tr_TR |
dc.contributor.scopusid | 55618956600 | tr_TR |
dc.contributor.scopusid | 23994946300 | tr_TR |
dc.contributor.scopusid | 7003323615 | tr_TR |
dc.contributor.scopusid | 6601953747 | tr_TR |
dc.subject.scopus | Citicoline; Brain Ischemia; Glycerylphosphorylcholine | en_US |
dc.subject.emtree | Caspase 3 | en_US |
dc.subject.emtree | Uridine | en_US |
dc.subject.emtree | Animal experiment | en_US |
dc.subject.emtree | Animal model | en_US |
dc.subject.emtree | Animal tissue | en_US |
dc.subject.emtree | Apoptosis | en_US |
dc.subject.emtree | Article | en_US |
dc.subject.emtree | Brain cortex | en_US |
dc.subject.emtree | Brain infarction size | en_US |
dc.subject.emtree | Controlled study | en_US |
dc.subject.emtree | Dose response | en_US |
dc.subject.emtree | Drug effect | en_US |
dc.subject.emtree | Hemisphere | en_US |
dc.subject.emtree | Hippocampal CA1 region | en_US |
dc.subject.emtree | Hippocampal CA3 region | en_US |
dc.subject.emtree | Hypoxic ischemic encephalopathy | en_US |
dc.subject.emtree | Immunoreactivity | en_US |
dc.subject.emtree | Neuroprotection | en_US |
dc.subject.emtree | Newborn | en_US |
dc.subject.emtree | Newborn disease | en_US |
dc.subject.emtree | Nick end labeling | en_US |
dc.subject.emtree | Nonhuman | en_US |
dc.subject.emtree | Priority journal | en_US |
dc.subject.emtree | Protein expression | en_US |
dc.subject.emtree | Rat | en_US |
dc.subject.emtree | Treatment duration | en_US |
Appears in Collections: | PubMed Scopus Web of Science |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.